Renub Research has announced the addition of "Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)" to its offering. For more details Please copy and paste the given link in browser: (http://www.renub.com/report/global-schizophrenia-prevalence-companies-analysis-drugs-forecast-2010---2015-47) Contact Us Ankit Mishra Relationship Manager Sales & Marketing Div Renub Research Email: info@renub.com Phone: +1-678-302-0700 (USA) +91-120-254-5750 (India) Web: http://www.renub.com/ Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

1. Global Schizophrenia Prevalence,
Companies Analysis & Drugs Forecast
Renub Research
www.renub.com
Publisher: Renub Research
Published: August, 2011

2. © Renub Research Page 2 of 8
Schizophrenia - Market Overview
Schizophrenia is a mental disorder characterized by disintegration of thought processes and of
emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or
bizarre delusions, or disorganized speech and thinking, or lack of concentration and
motivation and it is accompanied by significant social or occupational dysfunction. However
with proper medication this disease can be contained to a great extent and Schizophrenia
patients can lead a normal healthy life style.
At present lot of drugs for Schizophrenia are available in the market. From the introduction of
Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the
growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the
blockbuster drug which has changed the dynamics of the schizophrenia market. But the major
worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major
blockbuster drugs are going off-patent.
However, depot formulation is the emerging segment which has long term chances of success.
The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable
efficacy and a similar mechanism of action to that of the existing brands which will enter the
market by 2011.
Report Details
“Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)”
report published by Renub Research provides an in-depth analysis of the past, present and
future prospects. The report has been researched at source globally and features latest
available data covering:
 Global Schizophrenia Market has been covered from 2004-2019
 Global Schizophrenia patients in 7 countries
 Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon,
Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future
Market

3. © Renub Research Page 3 of 8
 Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna,
Relprevv) data analysis of Past, Present and Future Market
 Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin)
Future Trends Analyis
 Key Companies Strengths and Weakness analysis in Global Schizophrenia
Research Highlights
 The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million
by 2020
 From 2012 onwards Schizophrenia market is expected to show a decline
 Zyprexa is the most successful product in the history of neuroscience
 Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5
Billion by 2014.
 Risperdal Consta is the blockbuster injectable form of medicines and predicted that
the sale will cross US$ 2 Billion by 2014
 Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be
launched by 2011
Key Companies Analyzed
This section covers the business description, Strengths and Weakness of major players in
Global Schizophrenia Market. The key players analyzed in this section are – Eli Lilly and
Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer.
Data Sources
Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.

4. © Renub Research Page 4 of 8
Table of Contents
1. Executive Summary
2. Global Schizophrenia Market Past, Present & Future Trend
3. Prevalence of Schizophrenia in Top 7 Countries
3.1 United States of America
3.1.1 Schizophrenia Population & Future Scenario
3.2 Japan
3.2.1 Schizophrenia Population & Future Scenario
3.3 Germany
3.3.1 Schizophrenia Population & Future Scenario
3.4 France
3.4.1 Schizophrenia Population & Future Scenario
3.5 Italy
3.5.1 Schizophrenia Population & Future Scenario
3.6 United Kingdom
3.6.1 Schizophrenia Population & Future Scenario
3.7 Spain
3.7.1 Schizophrenia Population & Future Scenario
4. Global – Top 10 Schizophrenia Drug Brands Market Performance
4.1 Zyprexa (Olanzapine)
4.2 Seroquel (Quetiapine)
4.3 Geodon
4.4 Risperdal (Risperidone)
4.5 Lonasen
4.6 Serdolect
4.7 Abilify (Aripiprazole)
4.8 Invega (Paliperidone)
4.9 Fanapt (iloperidone)
4.10 Saphris (Asenapine)

5. © Renub Research Page 5 of 8
5. Global – Top 3 Schizophrenia Depot Formulations Brand Market Performance
5.1 Risperdal Consta (Risperidone)
5.2 Invega Sustenna (Paliperidone Palmitate)
5.3 Relprevv/Zyphdera (Olanzapine LAI)
6. Pipeline Developmental Agents – Future Trends
6.1 Lurasidone
6.2 Staccato (Loxapine Inhalation)
6.3 Cariprazine (RGH-188)
6.4 Pimavanserin
7. Key Companies
7.1 Eli Lilly and Company
7.1.1 Business Description
7.1.2 Strength & Weaknesses
7.2 Astrazeneca
7.2.1 Business Description
7.2.2 Strength & Weaknesses
7.3 Johnson & Johnson
7.3.1 Business Description
7.3.2 Strength & Weaknesses
7.4 Bristol-Myers Squibb
7.4.1 Business Description
7.4.2 Strength & Weaknesses
7.5 Pfizer
7.5.1 Business Description
7.5.2 Strength & Weaknesses

6. © Renub Research Page 6 of 8
Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com
Format
Report Title: Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 –
2015)
Single User
(Email from Publisher)
Hard Copy
(Mail Delivery)
CD – Rom
(Mail Delivery)
Global Site License
(Multiple User License)
US$ 850 US$ 950 US$ 950 US$ 1,400
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/report/global-schizophrenia-prevalence-companies-analysis-drugs-
forecast-2010---2015-47
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=47&pid=1169
To pay by Wire Transfer, please, fill in your contact details in the form below:

7. © Renub Research Page 7 of 8
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th
Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:

8. © Renub Research Page 8 of 8
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st
Floor
C-86, Sector -10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch